Far Infrared Radiation Treatment for Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:
NCT00573820
First received: December 12, 2007
Last updated: August 14, 2009
Last verified: August 2009

December 12, 2007
August 14, 2009
January 2006
February 2008   (final data collection date for primary outcome measure)
The primary end point is to determine the therapeutic effects of far infrared radiation on Prostate Cancer. [ Time Frame: 2 years and 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00573820 on ClinicalTrials.gov Archive Site
The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of cancer (Bladder and Testis). [ Time Frame: 2 years and 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Far Infrared Radiation Treatment for Prostate Cancer
Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Prostate Cancer

A study to determine the use of far infrared radiation for the treatment of prostate cancer.

Our initial assessment indicates that electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to cure a number of diseases, including prostate cancer.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostatic Neoplasms
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
1
Intervention: Radiation: Far Infrared Radiation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
4
December 2008
February 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Persons with Prostate, Bladder or Testicular Cancer.

Exclusion Criteria:

  • None
Male
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00573820
GAAD-PC-CTP1
Yes
Dr. Kwasi Donyina/Founder & President, GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
Not Provided
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Director: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP